Status:
UNKNOWN
Decline in Renal Concentration Ability in Lithium Treated Patients
Lead Sponsor:
Radboud University Medical Center
Conditions:
Lithium Toxicities
Bipolar Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Lithium therapy is cornerstone in therapy of bipolar disorders. A well known side-effect of lithium therapy is a urinary concentration defect which manifests in it's most severe form as nephrogenic di...
Eligibility Criteria
Inclusion
- included in the previous study
- men and women
- age ≥ 18 years
Exclusion
- General contra-indications for participation in a trial:
- inability to give informed consent
- pregnancy
- unstable psychiatric condition
- Alternative causes of (nephrogenic) diabetes insipidus:
- hypokalemia (plasma potassium \< 3.0 mmol/l)
- severe hypercalcemia (albumin-corrected plasma calcium \> 2.80 mmol/l)
- hyperglycemia (plasma glucose \> 10.0 mmol/l)
- history of amyloidosis, Sjögren's syndrome or Sickle cell anemia
- previous treatment with ifosfamide
- established primary polydipsia or central diabetes insipidus
- Contra-indications for dDAVP administration:
- inability to comply with water restriction
- renal insufficiency (GFR \< 45 ml/min/1.73 m2)
- hyponatremia (plasma sodium \< 130 mmol/l)
- instable angina pectoris
- decompensated cardial insufficiency
- Other:
- concomitant treatment with desmopressin or democlocycline
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT05307042
Start Date
May 1 2022
End Date
December 1 2022
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Canisius Wilhelmina Ziekenhuis
Nijmegen, Gelderland, Netherlands, 6532SZ